MARATTO

article · Journal of Taibah University for Science

Design of new captopril mimics as promising ACE inhibitors: ADME, pharmacophore, molecular docking and dynamics simulation with MM-PBSA and PCA calculations

202310 citationsOpen accessBadr University in Cairo

Abstract

New pyrrolidine derivatives with more than 50% structural similarity with captopril were designed to get new captopril mimics with superior potential to act on both peripheral and central ACE. Further optimization was carried out through pharmacophoric mapping, then pharmacokinetics of these compounds were analyzed, 42 derivatives were selected for further study, as they exhibited potential to pass through BBB. Molecular docking on ACE using captopril and lisinopril as reference drugs was performed, and Compound 28 (2-Pyrrolidin-2-ylidene-N-thiomorpholin-4-ylmethyl-malonamic acid ethyl ester) showed the best docking scores, proving its superiority over captopril and comparability to lisinopril. Further molecular dynamics simulations and energy calculations demonstrated binding stability and close mimicry to both drugs. The results indicate that Compound 28 is a promising candidate for further investigations as a potential drug to act centrally and peripherally. Compound 28 can be synthesized by reacting Cyano-pyrrolidin-2-ylidene-acetic acid ethyl ester through Mannich reaction with thiomorpholine and formaldehyde.

Research topics

  • Chemical Reaction Mechanisms
  • Enzyme function and inhibition
  • Synthesis and Biological Evaluation

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/16583655.2023.2210348

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.